|
|||||
|
|
Lessons for general vaccinology research from attempts to develop an HIV vaccine |
|
| Institution: | 1. Chandrubeksa Hospital, RTAF, Nakhon Pathom 73180, Thailand;2. Queen Saovabha Memorial Institute, Thai Red Cross Society, Bangkok 10330, Thailand;3. Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand;1. BehaviourWorks Australia, Monash Sustainable Development Institute, Monash University, Melbourne, Australia;2. Immunisation Section, Health Protection Branch, Department of Health and Human Services, Victorian State Government, Melbourne, Australia;3. Public Sector Innovation, Department of Premier and Cabinet, Victorian State Government, Melbourne, Australia;4. Behavioural Insights Unit, Department of Premier and Cabinet, Victorian State Government, Melbourne, Australia;1. Instituto Nacional de Salud, Bogotá, Colombia;2. GSK, Panama City, Panama;1. Center of Pathogen Biology and Immunology, Department of Microbiology and Immunology, Shantou University Medical College, Shantou 505041, Guangdong, China;2. Guangdong Provincial Key Laboratory of Infectious Disease and Molecular Immunopathology, Shantou University Medical College, Shantou 505041, Guangdong, China;3. Department of Anesthesiology, The Second Xiangya Hospital of Central South University, Changsha 410011, China;1. National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada;2. Biochemistry & Medical Genetics, University of Manitoba, Winnipeg, MB, Canada;3. Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB, Canada;1. Biomedical Research Institute, the National Institute of Advanced Industrial Science and Technology (AIST), 1-1-1, Higashi, Tsukuba, Ibaraki 305-8566, Japan |
| Abstract: | In the past when large investments have been made in tackling narrow scientific challenges, the enormous expansion in our knowledge in one small area has had a spill-over effect on research and treatment of other diseases. The large investment in HIV vaccine development in recent years has the potential for such an effect on vaccine development for other diseases. HIV vaccine developers have experienced repeated failure using the standard approaches to vaccine development. This has forced them to consider immune responses in greater depth and detail. It has led to a recognition of the importance of epitopic specificity in both antibody and T cell responses. Also, it has led to an understanding of the importance of affinity maturation in antibody responses and the quality of T cell responses in T cell-mediated immunity. It has advanced the development of many novel vaccine vectors and vehicles that are now available for use in other vaccines. Further, it has focused attention on the impact of research funding mechanisms and community engagement on vaccine development. These developments and considerations have implications for vaccinology more generally. Some suggestions are made for investigators working on other “hard-to-develop” vaccines. |
| Keywords: | HIV vaccines Vaccinology Vaccine design Affinity maturation Epitopes T cell-based vaccines CAR-T"} {"#name":"keyword" "$":{"id":"k0040"} "$$":[{"#name":"text" "_":"chimeric antigen receptor T cells BNAbs"} {"#name":"keyword" "$":{"id":"k0050"} "$$":[{"#name":"text" "_":"broadly neutralizing antibodies BCR"} {"#name":"keyword" "$":{"id":"k0060"} "$$":[{"#name":"text" "_":"B cell receptor TfH"} {"#name":"keyword" "$":{"id":"k0070"} "$$":[{"#name":"text" "_":"T follicular helper cell TfR"} {"#name":"keyword" "$":{"id":"k0080"} "$$":[{"#name":"text" "_":"T follicular regulatory cell ADCC"} {"#name":"keyword" "$":{"id":"k0090"} "$$":[{"#name":"text" "_":"antibody-dependent cellular cytotoxicity |
| 本文献已被 ScienceDirect 等数据库收录！ | |